Pharmacological inactivation of MYC for the treatment of cancer

被引：17

作者：

Felsher, DW ^{[1
]}

Bradon, N

机构：

[1] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA

[2] Stanford Univ, Dept Pathol, Div Oncol, Stanford, CA 94305 USA

来源：

DRUG NEWS & PERSPECTIVES | 2003年 / 16卷 / 06期

关键词：

CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; C-MYC; ANTISENSE OLIGONUCLEOTIDE; NEOPLASTIC PHENOTYPE; GENOMIC INSTABILITY; SMALL-MOLECULE; CELLS; INHIBITOR; TUMORIGENESIS;

D O I：

10.1358/dnp.2003.16.6.829309

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The overexpression of the MYC proto-oncogene has been implicated in the pathogenesis of most types of human cancer. Recent experimental observations indicate that the inactivation of MYC may be effective in the treatment of neoplasia. Several different strategies have been employed to develop novel drugs that may be effective to target the inactivation of MYC for the treatment of cancer. Some of these strategies are discussed. (C) 2003 Prous Science. All rights reserved.

引用

页码：370 / 374

页数：5

共 37 条

[1]

Arora V, 2000, J PHARMACOL EXP THER, V292, P921

[2] Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats [J].

Arora, V ;

Knapp, DC ;

Reddy, MT ;

Weller, DD ;

Iversen, PL .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (04) :1009-1018

[3] MAD - A HETERODIMERIC PARTNER FOR MAX THAT ANTAGONIZES MYC TRANSCRIPTIONAL ACTIVITY [J].

AYER, DE ;

KRETZNER, L ;

EISENMAN, RN .

CELL, 1993, 72 (02) :211-222

[4] Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts [J].

Berg, T ;

Cohen, SB ;

Desharnais, J ;

Sonderegger, C ;

Maslyar, DJ ;

Goldberg, J ;

Boger, DL ;

Vogt, PK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (06) :3830-3835

[5] MOLECULAR THEMES IN ONCOGENESIS [J].

BISHOP, JM .

CELL, 1991, 64 (02) :235-248

[6] EFFECTS OF THE MYC ONCOGENE ANTAGONIST, MAD, ON PROLIFERATION, CELL CYCLING AND THE MALIGNANT PHENOTYPE OF HUMAN BRAIN-TUMOR CELLS [J].

CHEN, J ;

WILLINGHAM, T ;

MARGRAF, LR ;

SCHREIBERAGUS, N ;

DEPINHO, RA ;

NISEN, PD .

NATURE MEDICINE, 1995, 1 (07) :638-643

[7] Essential role for oncogenic Ras in tumour maintenance [J].

Chin, L ;

Tam, A ;

Pomerantz, J ;

Wong, M ;

Holash, J ;

Bardeesy, N ;

Shen, Q ;

O'Hagan, R ;

Pantginis, J ;

Zhou, H ;

Horner, JW ;

Cordon-Cardo, C ;

Yancopoulos, GD ;

DePinho, RA .

NATURE, 1999, 400 (6743) :468-472

[8]

COTTER FE, 1994, ONCOGENE, V9, P3049

[9] c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations [J].

D'Cruz, CM ;

Gunther, EJ ;

Boxer, RB ;

Hartman, JL ;

Sintasath, L ;

Moody, SE ;

Cox, JD ;

Ha, SI ;

Belka, GK ;

Golant, A ;

Cardiff, RD ;

Chodosh, LA .

NATURE MEDICINE, 2001, 7 (02) :235-239

[10] Inhibition of human chorionic gonadotropin β-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells [J].

Devi, GR ;

Oldenkamp, JR ;

London, CA ;

Iversen, PL .

PROSTATE, 2002, 53 (03) :200-210

← 1 2 3 4 →